Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-18	0.000100 $	-75.00%	6,918
26-06-17	0.000400 $	+300.00%	229,696
26-06-16	0.000100 $	-75.00%	856
26-06-15	0.000400 $	+300.00%	7,160

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 13:44:41 2026-06-18 EDT			5-day change	1st Jan Change
0.000100 ^USD	-75.00%		0.00%	-75.00%

25-03-23	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
25-03-18	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI

Market Cap	6.17M 5.38M 4.98M 4.66M 8.74M 582M 8.79M 59.07M 22.89M 286M 23.15M 22.65M 994M	P/E 2022	-0.48x	P/E 2023	-1.34x
Enterprise Value	-71.28M -62.15M -57.56M -53.89M -101M -6.73B -102M -683M -265M -3.31B -268M -262M -11.5B	EV / Sales 2022	-4.44x	EV / Sales 2023	12.6x
Free-Float	99.85%	Yield 2022 *	-	Yield 2023	-

25-03-23	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
25-03-18	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI
25-02-28	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares	MT
25-02-28	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025	CI
25-02-28	Syros Pharmaceuticals, Inc. Announces Management Changes	CI
24-12-22	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index	CI
24-11-13	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
24-11-13	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
24-11-13	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC	CI
24-11-12	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	CI
24-10-31	Syros Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024

24-11-13	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
24-11-13	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
24-11-13	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
23-05-11	JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	MT

Syros Pharmaceuticals, Inc. Stock

Stocks

SYRS

US87184Q2066

Biotechnology & Medical Research

Valuation: Syros Pharmaceuticals, Inc.

Chart: Syros Pharmaceuticals, Inc.

Latest news : Syros Pharmaceuticals, Inc.

Analysts' recommendations: Syros Pharmaceuticals, Inc.

Press Releases: Syros Pharmaceuticals, Inc.

News in other languages: Syros Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Syros Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

25-02-28	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
24-11-18	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
24-11-13	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
24-11-12	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
24-11-01	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ

23-07-24	USA-Les valeurs à suivre à Wall Street (actualisé)
21-08-05	Bourse Zurich: le SMI termine dans le vert juste sous les 12'200 points
21-08-05	Roche signe un accord de livraison avec Syros Pharmaceuticals

1 day	-75.00%
Current month	-50.00%
1 month	-50.00%
3 months	-50.00%
6 months	-87.50%
Current year	-75.00%

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.04
3 years	0		8.17
5 years	0		57.7
10 years	0		243.75

Manager	Title	Age	Since
Gerald Quirk CEO	Chief Executive Officer	58	2024-11-21
Karen Hunady IRC	Investor Relations Contact	-	2022-09-30
Matthew Foster PRN	Corporate Officer/Principal	-	2025-02-28

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-12-01	Nancy Simonian	Sell	Chief Executive Officer	37,070	0.1382%
24-11-24	Nancy Simonian	Sell	Chief Executive Officer	134,713	0.5025%
24-11-18	Gerald Quirk	Sell	Chief Financial Officer	46,657	0.1740%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYROS PHARMACEUTICALS, INC.	-75.00%	0.00%	-99.55%	-100.00%	2.68K
LONZA GROUP AG	+1.44%	+1.71%	-10.98%	-5.59%	43.13B
REVOLUTION MEDICINES, INC.	+3.31%	+5.93%	+310.97%	+532.23%	34.65B
BEONE MEDICINES AG	+2.84%	+2.14%	+9.34%	+45.55%	30.03B
IQVIA HOLDINGS INC.	-1.70%	-7.54%	+8.43%	-21.54%	28B
CELLTRION, INC.	-1.90%	-1.56%	+10.24%	+22.81%	24.45B
ASCENDIS PHARMA A/S	-0.14%	+5.86%	-	-	14.34B
MEDPACE HOLDINGS, INC.	+0.68%	-1.53%	+48.76%	+108.76%	13.14B
EUROFINS SCIENTIFIC SE	-0.57%	-2.43%	+5.08%	+6.76%	12.53B
IONIS PHARMACEUTICALS, INC.	-0.26%	+1.15%	+98.13%	+79.60%	12.25B
Average	-7.13%	+0.66%	+42.27%	+74.29%	21.25B
Weighted average by Cap.	+0.77%	+1.27%	+65.47%	+111.07%

	2022	2023
Net sales	14.88M 12.97M 12.02M 11.25M 21.1M 1.4B 21.22M 143M 55.24M 691M 55.86M 54.66M 2.4B	9.94M 8.66M 8.02M 7.51M 14.09M 938M 14.17M 95.18M 36.89M 461M 37.3M 36.5M 1.6B
Net income	-94.65M -82.53M -76.43M -71.55M -134M -8.93B -135M -907M -351M -4.4B -355M -348M -15.26B	-165M -143M -133M -124M -233M -15.53B -235M -1.58B -611M -7.64B -618M -605M -26.54B
Net Debt	-139M -121M -112M -105M -197M -13.09B -198M -1.33B -515M -6.44B -521M -510M -22.37B	-77.45M -67.53M -62.54M -58.55M -110M -7.31B -110M -742M -288M -3.6B -291M -284M -12.49B